Ha! There is always hope I guess. Other posters have been correct in that this pattern repeats itself. A RS and NSPX does nothing to (or doesn't want to) or can't defend the PPS and there is a low volume slide back to pre RS prices. Frustrating for sure. It has happened before and may happen again. For years Genspera/Inspyr proponents blamed the lack of development of mipsagargin for the lack of a supply chain for thapsigargin. The hope is now with the pending patent for Phyton some one will pick up mipsagargin and take it into PH III.